Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Aug;130(8):453-9.
doi: 10.1007/s00432-004-0575-6. Epub 2004 Jun 15.

Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines

Affiliations

Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines

Manish Patel et al. J Cancer Res Clin Oncol. 2004 Aug.

Abstract

Purpose: The addition of oxaliplatin or CPT-11 to 5-FU has become common practice in the treatment of colorectal cancer. It is not known, however, which fluoropyrimidine drug (5-FU, FUdR, or FUR) will produce superior cytotoxicity when combined with either oxaliplatin or CPT-11. The purpose of the study was to determine the effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of all three fluoropyrimidines.

Methods: HT-29 cells were exposed for 2 h to IC(10), IC(30), and IC(70) of oxaliplatin and CPT-11. Subsequently, cells were exposed for 24 h to IC(10), IC(30), and IC(70) of 5-FU, FUdR, and FUR. Cytotoxicity was measured by the MTT assay. Nucleic acid incorporation of [(3)H]fluoropyrimidine was then compared in the presence and absence of oxaliplatin or CPT-11 pretreatment.

Results: Synergistic cytotoxicity was displayed when IC(30) of oxaliplatin or CPT-11 was combined with IC(10) and IC(30) of the fluoropyrimidines. One fluoropyrimidine did not achieve superior cytotoxicity over the others. After pretreatment with oxaliplatin or CPT-11, cytotoxic antagonism was observed as the concentration of a fluoropyrimidine increased up to IC(70). The increasing cytotoxic antagonism correlated with decreases in fluoropyrimidine nucleic acid incorporation. The most significant incorporation difference existed within the 5-FU treated group.

Conclusions: No single fluoropyrimidine is more cytotoxically effective over the others when combined with oxaliplatin or CPT-11. Correlation of cytotoxic antagonism to the inhibition of fluoropyrimidine nucleic acid incorporation implies difficulties in drug transport and/or metabolism only after oxaliplatin or CPT-11 pretreatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Metabolic pathways for the fluoropyrimidines. FU, FUdR, and FUR are 5-fluorouracil, 5-fluoro-2’-deoxyuridine, and 5-fluorouridine, respectively. FdUMP is 5-fluoro-2’deoxyuridine-5’-monophosphate and FdUTP is 5-fluoro-2’deoxyuridine-5’-triphosphate. FUMP, FUDP, and FUTP are 5-fluorouridine-5’mono-, di-, and triphosphate, respectively. The enzyme thymidylate synthase is indicated by T.S. The dotted arrow displays the inhibitory action of FdUMP on T.S. activity

Similar articles

Cited by

References

    1. Agarwal RP, Han T, Fernandez M (2001) Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 61:39–47 - PubMed
    1. Ansfield FJ, Curreri AR (1963) Further clinical comparison between 5-Fluorouracil (5-FU) and 5-fluoro-2’-deoxyuridine (5-FUDR). Cancer Chemother Rept 32:101–105 - PubMed
    1. Arisawa Y, Sutanto-Ward E, Dalton RD, Sigurdson ER (1994) Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance. J Surg Oncol 56:75–80 - PubMed
    1. Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics 1994. CA Cancer J Clin 44:7–26 - PubMed
    1. Buroker T, Samson M, Correa J, Fraile R, Vaitkevicius VK (1976) Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. Cancer Treat Rep 60:1277–1279 - PubMed

MeSH terms

LinkOut - more resources